

Notes of: Meeting of the Northern and Eastern Devon Formulary Interface Group

Thursday 28<sup>th</sup> November 2013: 9:00am – 11:00am. Meeting Room C, Tiverton Hospital

<b>Present</b>	Chris Roome (CR)– Head of Clinical Effectiveness, Chair	NEW Devon CCG
	Gareth Franklin (GF) – Clinical Guidance Manager	NEW Devon CCG
	Sam Smith (SS) – Locality Medicines Optimisation Pharmacist	NEW Devon CCG
	Carol Albury (CA) - Locality Medicines Optimisation Pharmacist	NEW Devon CCG
	Matt King (MK) – GP, Coleridge Medical Centre	NEW Devon CCG
	Carol Webb (CW) – Joint Formularies Technician	NEW Devon CCG
	Stuart Kyle (SKY) – DTC Chair / Consultant Rheumatologist	NDDH
	Hugh Savill (HS) – GP, Castle Place Surgery	NEW Devon CCG
	Simon Kay (SK) – GP, Haldon House Surgery	NEW Devon CCG
	Andrew Harrison (AH) – GP, The South Lawn Medical Practice	NEW Devon CCG
	Iain Carr (IC) – Medicines Optimisation Pharmacist	NEW Devon CCG
	Tawfique Daneshmend (TD)– DTC Chair/Consultant Gastroenterologist	RD&E
	Darunee Whiting (DW) – GP, Northam Surgery	NEW Devon CCG
Susie Harris (SHa) – Consultant, Elderly Care	RD&E	

<b>Apologies</b>	Beverly Baker (BB) – Non Medical Prescribing Lead	NEW Devon CCG
	Tracey Foss (TF) – Chief Pharmacist	RD&E
	Ross Mitchell (RM)	Dorset Healthcare
	Stephen Hunt (SH) – GP, Waterside Practice	NEW Devon CCG
	Carole Knight (CK) – Formulary Pharmacist	NDDH
	Petrina Trueman (PT) - Joint Formularies Pharmacist	NEW Devon CCG
	Carol Peacock (CP) – Medicines Optimisation Pharmacist	NEW Devon CCG

1. Welcome and Apologies – noted above  
Susie Harris, new member to the group was welcomed and introductions made

2. **Notes of previous meeting**  
The notes of the meeting of 24<sup>th</sup> October 2013 were agreed.

**Action list from the previous minutes, not on the agenda**

- **Palliative care guidance:** Next meeting of the committee is in January. Agreed to take this item off the action list and to report when progress has been made
- **New Anticoagulation guidance:** The rivaroxaban guidance has be reformatted and added to the test formulary website. To re-send the link to this re-formatted guidance to the members of the group
- **Infant Feeds Guidance:** The infant feeds guidance has been added to the test formulary site, with a link to the RD&E website for detailed specialist guidance. Comment from North Devon requested key prescribing information be included on the formulary website (including durations of treatment).

CW

**Action: to look at the RD&E guidance to see which points should be included on the formulary page**

IC/CA

- **Updated osteoporosis pathway:** There was discussion about the funding of

denosumab treatment, which is available, and who should be administering. There was discussion about informing the LMC about the group of patients who would be treated in primary care

**Action: to take the issue of denosumab treatment in primary care to the LMC** **CR**

- **ENT Chapter:** Comments received from North Devon specialists

**Action: To bring a draft chapter to the December meeting** **GF**

### 3. Brands

There was a discussion about changing to different brands in the formulary. It was acknowledged that, to reduce the costs in prescribing, to recommend a specific brand in some instances are appropriate. Starting new patients to the specified brand is preferred by practices over switching current patients.

### 4. Chapter 1 Gastrointestinal System

The merger of this chapter has been done by Iain Carr who detailed to the meeting the significant changes.

- Gaviscon infant, is added (currently only in the North Devon formulary)
- There was discussion about the dose of PPI in acid related dyspepsia. It was agreed to just include the 20mg omeprazole and 15mg lansoprazole
- Mesalazine

- it was suggested that Octasa mr be added as an alternative brand due to warnings about the DBP in the coatings of the 800mg Asacol. This was agreed in principle as there is work being done by Bryan Foresheew in this area.
- General branded prescribing for mesalazine was discussed

**Action: check NICE guidance** **IC**

- The note about renal impairment to be expanded and defined.

- Budesonide, it was agreed to define the brand as Budenofalk
- Prednisolone, it was agreed to add in the 5mg suppositories
- Bowel cleansing preparations, there is an increase in the preparations used

**Action: to send a list of these preparations to IC** **TD**

- Phenol oily is no longer used so can be deleted
- Diltiazem cream, to highlight that this is a second choice after GTN
- Constipation guidance
  - To define Laxido as the preferred brand of macrogol
  - To delete the word 'ineffective' in the note about when to use lactulose
  - Phosphate enemas are in the guidance but need to be included as a drug entry
- Irritable Bowel Syndrome
  - A note about low FODMAP diet needs to be worded and included, stressing that the patients need to be seen by a specialist/dietician before commencing this
  - To delete the section about psychological interventions
  - Crohn's disease, to add information about mesalazine in the colonic section
- Omeprazole IV infusion, to amend the wording to what is included in the BNF

## 5. Pain section

This merger work has been completed by Carl Peacock, GF reported on this and the significant changes

- It was agreed to delete co-dydramol and dihydrocodeine from the formulary
- Oromorph concentrated oral solution to be defined as a yellow drug, to highlight its difference from the standard strength solution
- Zomorph capsules to be highlighted as the first-choice for new patients, and a note to be put on to Scriptswitch.
- Fentanyl patches, the preferred brand was discussed. It was agreed to include Matrifen in the formulary, GF to contact acute trusts about Durogesic.

**Action: to check with NDDH and RD&E about just using Matrifen**

GF

- To delete the morphine equivalences to Transtec patches as these are non-formulary
- Abstral tablets, there was discussion on the use of these. There is national work being done to look at the prescribing of oral fentanyl

**Action: to look at the prescribing data for these preparations. To include appropriate wording for its place in treatment**

CA/GF

- Opioid conversion tables, there was discussion about the difficulties with the oxycodone conversion taken from the BNF.

**Action: to send SHa the conversion tables proposed for the South & West Formulary for comment and possible inclusion**

GF

Due to time constraints the remainder of this item will be discussed at the next meeting

The meeting was concluded at this point and the remainder of the items will be re-scheduled to later meetings

It was also noted that the proposed formulary launch will also need to be delayed to the beginning of the New Year.

There were several apologies for the next meeting on the 19<sup>th</sup> December, this may be re-arranged.

**Next meeting: Thursday 19<sup>h</sup> December 2013** Meeting Room C, Tiverton Hospital, Tiverton EX16 6NT

**DATE TO BE CONFIRMED**

Northern & Eastern Formulary – Action Log			
Date	Action	Responsible	
Nov 2013	<b>New anticoagulation guidance</b> To re-send the link to the committee	CW	Complete
Nov 2013	<b>Infant Feeds Guidance:</b> To look at the RD&E guidance to see if any points could be extracted and put on the formulary page	IC/CA	
Nov 2013	<b>Updated osteoporosis pathway</b> To take the issue of denosumab treatment in primary care to the LMC	CR	
Nov 2013	<b>GI Chapter</b> <ul style="list-style-type: none"> <li>○ to check what NICE says about branded mesalazine prescribing</li> <li>○ to send the list of bowel cleansing preparations to IC</li> </ul>	IC TD	
Nov 2013	<b>ENT Chapter</b> Final draft to be brought to the December meeting	GF	
Nov 2013	<b>Pain section</b> <ul style="list-style-type: none"> <li>○ to check with NDDH and RD&amp;E about just using Matrifen as the preferred brand of fentanyl patches</li> <li>○ to look at the prescribing data for these preparations</li> <li>○ to include appropriate wording for place of Abstral in treatment</li> <li>○ to send SHa the opioid conversion tables proposed for the South &amp; West Formulary for comment and possible inclusion</li> </ul>	GF CA GF GF	